Lung Cancer Outcomes Significantly Improved With Immunotherapy-Based Treatment Given Before and After Surgery

Results from the phase 3 AEGAN trial demonstrated that pre-surgical immunotherapy and chemotherapy followed by post-surgical immunotherapy improved event-free survival and pathologic complete response compared to chemotherapy alone among patients with operable NSCLC.

Access the full article to read more here.